FDA rejects new obesity drug Qnexa
Saturday, October 30, 2010 - 02:20
in Health & Medicine
The US Food and Drug Administration has rejected a marketing request by Vivus for its new obesity treatment called Qnexa, because it considers it a health risk, the California-based biotech firm said in a statement.